MarketVIEW: Staphylococcus aureus vaccines

Contents – Summary presentation (MS PowerPoint based)
Author’s note
Contents
Executive Summary
Commercial model – key outputs
Total global available market ($000s all scenarios), pricing level 1
Total global available market ($000s all scenarios), pricing level 2
Total global available market ($000s all scenarios), pricing level 3
Total predicted demand (doses 000s all scenarios)
Total available volume per vaccine segment, US – 2025
Model forecast comparisons: March 2010 v current (April 2012) – volume/value
Model forecast comparisons: March 2010 v current (April 2012) – per segment
Company revenue summary
Modelling commercial potential
The role of S.aureus vaccine
Characteristics of the ideal S.aureus vaccine
S.aureus vaccine: target product profile (minimum)
S.aureus vaccine: target product profile (ideal)
Target populations: vaccination strategies
Vaccine target populations: overview
Vaccine target populations: scenario definition
Markets included in model
Commercial model assumptions: general
Commercial model assumptions: short-term risk
Commercial model assumptions: chronic risk
Model forecast assumptions: comparing March 2010 with current (April 2012)
Notes on Pricing
S.aureus vaccines: R&D pipeline
Competitor landscape overview
S.aureus vaccine: estimated launch dates
Pfizer: SA4Ag – background
Pfizer: SA4Ag – Phase I data
GSK: GSK2392103A/Nabi
Other vaccine candidates
Merck & Co/Intercell AG – V710
Staphylococcus aureus: update on infection control
Situation overview: MRSA infection control
US situation
Review of latest epidemiology
Acute care hospitals: US
Acute care hospitals: pan-European
Acute care hospitals: UK
Acute care hospitals: Germany
Acute care hospitals: France
Europe: methicillin-resistance disease trends
MRSA: colonization rates
Backup material: methodology
Methodology: general comments – CABG, ESRD & LTCFs
Methodology: general comments – ICU/elective
Methodology: general comments – diabetics
Bibliography
Disclaimer
About VacZine Analytics
PAGES: 80 MS PowerPoint slides, fully referenced/sourced. Available in .pdf form
Contents – Vaccine demand model (MS Excel-based)
Title sheet
TOTAL CHARTS – forecast to 2030
CHARTS VALUE – pricing level 1
CHARTS VALUE – pricing level 2
CHARTS VALUE – pricing level 3
CHARTS VOLUME – HIGH
VALUE SUMMARY – pricing level 1
VALUE SUMMARY – pricing level 2
VALUE SUMMARY – pricing level 3
Competitor summary (Base scenario)
US (all scenarios LO/BASE/HIGH)
Canada
UK
Germany
France
Spain
Italy
Australia
Japan
Country target populations – forecast to 2030
Source material
LTCFs
CABG
Orthopaedic
ESRD
Hospital admissions
Elective admissions
Diabetes
US segments
Back page
About VacZine Analytics
Disclaimer
WORKSHEETS: ~65